Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

This study has been completed.

Study NCT01452815 Information provided by Tranzyme, Inc.

First Received on October 12, 2011. Last Updated on April 24, 2013 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Additional conditions recognized in this trial

Diabetes Mellitus

More general conditions related to this trial

Interventions listed in this trial

Placebo
10mg TZP-102
20mg TZP-102

Sponsors listed in this trial

Tranzyme, Inc.